Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Receives Orphan Drug Designation for Elatnexor...
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) has announced that the FDA had granted its novel oral, Selective Inhibitor of Nuclear Exports (SINE) compound, eltanexor, an...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Commencement Of SLS-004 Preclinical Study In...
Seelos Therapeutics Inc. (NASDAQ:SEEL) has announced the commencement of a preclinical SLS-004 study in Parkinson’s disease through a lentiviral vector that is all in...
MAKE IT MODERN
LATEST REVIEWS
Vallon Pharmaceuticals Inc. (NASDAQ: VLON) Announce Topline Finding Results For Pivotal...
Vallon Pharmaceuticals Inc. (NASDAQ: VLON) has announced topline results from the pivotal SEAL study assessing ADAIR, a novel abuse-deterrent formula for immediate release dextroamphetamine...
MAKE IT MODERN
PERFORMANCE TRAINING
Homology Medicines Inc. (NASDAQ: FIXX) Commences Phase 1 HMI-203 Study In Hunter Syndrome...
Homology Medicines Inc. (NASDAQ: FIXX) has commenced the Phase 1 study for HMI-203 for Hunter syndrome or mucopolysaccharidosis Type II treatment in adults. HMI-203...
Avalon GloboCare Corp. (NASDAQ: ALBT) surges Over 300% Amid Promotional Activity and NASDAQ Compliance...
Avalon GloboCare Corp. (NASDAQ: ALBT) has been making waves in the stock market, with its shares skyrocketing over 300%. This remarkable surge...
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Appoints a New Chief Financial Officer
Adaptive Biotechnologies Corp (NASDAQ: ADPT) has appointed a new chief financial officer (CFO). Tycho Peterson, who will fill the role, has decades of experience...
Vertex (NASDAQ:VRTX) Announce EMA Type II Variation Marketing Authorization Application For Expansion Of KAFTRIO®...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has announced that the European Medical agencies have validated its Type II variation Marketing Authorization Application for KAFTRIO®.
MAA for expansion...
Pluristem Therapeutics Inc. (NASDAQ: PSTI) Announces Topline Second Phase Dose Escalation Study Evaluating PLX-PAD...
Pluristem Therapeutics Inc. (NASDAQ: PSTI) has released topline findings from phase 2 dose-escalation trials evaluating the efficacy and safety of intramuscular PLX-PAD cells injection...
MAKE IT MODERN
